Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Russell Trenary, President and CEO, will present at the conference and be available for one-on-one meetings with qualified investors.
The company recently achieved regulatory approval in the European Union and the United Kingdom for the first authorized ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET for registered attendees and on the company's website for 90 days following the event.
Outlook Therapeutics (Nasdaq: OTLK), una compagnia biofarmaceutica, ha annunciato la sua partecipazione alla 26° Conferenza Annuale Globale sugli Investimenti H.C. Wainwright, che si terrà dal 9 all'11 settembre 2024 a New York. Russell Trenary, Presidente e CEO, presenterà alla conferenza e sarà disponibile per incontri individuali con investitori qualificati.
L'azienda ha recentemente ottenuto l'approvazione normativa nell'Unione Europea e nel Regno Unito per la prima formulazione oftalmica autorizzata di bevacizumab per il trattamento della degenerazione maculare legata all'età umida (wet AMD). Una videoconferenza della presentazione sarà disponibile on-demand dal 9 settembre 2024 alle 7:00 AM ET per i partecipanti registrati e sul sito web dell'azienda per 90 giorni dopo l'evento.
Outlook Therapeutics (Nasdaq: OTLK), una compañía biofarmacéutica, anunció su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright del 9 al 11 de septiembre de 2024 en Nueva York. Russell Trenary, Presidente y CEO, presentará en la conferencia y estará disponible para reuniones individuales con inversores calificados.
La compañía recientemente obtuvo la aprobación regulatoria en la Unión Europea y el Reino Unido para la primera formulación oftálmica autorizada de bevacizumab para tratar la degeneración macular relacionada con la edad húmeda (wet AMD). Una transmisión por video de la presentación estará disponible bajo demanda desde el 9 de septiembre de 2024 a las 7:00 AM ET para los asistentes registrados y en el sitio web de la compañía durante 90 días después del evento.
Outlook Therapeutics (Nasdaq: OTLK)는 생명공학 제약 회사로, 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. Russell Trenary 회장 겸 CEO는 컨퍼런스에서 발표하고 자격을 갖춘 투자자와의 일대일 미팅을 위해 자리를 마련할 것입니다.
회사는 최근 유럽연합 및 영국에서 젊은 습식 연령 관련 황반 변성(wet AMD) 치료를 위한 첫 번째 허가된 안과용 bevacizumab 제형에 대한 규제 승인을 받았습니다. 발표의 비디오 웹캐스트는 2024년 9월 9일 오전 7:00 ET부터 등록된 참석자를 위해 주문형으로 제공되며, 행사 후 90일 동안 회사 웹사이트에서도 시청할 수 있습니다.
Outlook Therapeutics (Nasdaq: OTLK), une société biopharmaceutique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright qui se déroulera du 9 au 11 septembre 2024 à New York. Russell Trenary, Président et CEO, présentera lors de la conférence et sera disponible pour des réunions individuelles avec des investisseurs qualifiés.
La société a récemment obtenu l'approbation réglementaire dans l'Union Européenne et au Royaume-Uni pour la première formulation ophtalmique autorisée de bevacizumab pour traiter la dégénérescence maculaire liée à l'âge humide (wet AMD). Une retransmission vidéo de la présentation sera disponible à la demande à partir du 9 septembre 2024 à 7h00 ET pour les participants enregistrés et sur le site de l'entreprise pendant 90 jours après l'événement.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt, die vom 9. bis 11. September 2024 in New York stattfindet. Russell Trenary, Präsident und CEO, wird auf der Konferenz präsentieren und sich für Einzelgespräche mit qualifizierten Investoren zur Verfügung stellen.
Das Unternehmen erhielt kürzlich die regulatorische Genehmigung in der Europäischen Union und im Vereinigten Königreich für die erste autorisierte ophthalmologische Formulierung von Bevacizumab zur Behandlung der feuchten altersbedingten Makuladegeneration (wet AMD). Eine Videoübertragung der Präsentation wird ab dem 9. September 2024 um 7:00 Uhr ET für registrierte Teilnehmer auf Abruf verfügbar sein und für 90 Tage nach der Veranstaltung auf der Website des Unternehmens zu finden sein.
- None.
- None.
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the H.C. Wainwright Global Investment Conference?
What recent regulatory approval did Outlook Therapeutics (OTLK) receive in 2024?
How can investors access Outlook Therapeutics' (OTLK) presentation at the H.C. Wainwright conference?
Who will represent Outlook Therapeutics (OTLK) at the H.C. Wainwright conference in September 2024?
